Previous 10 | Next 10 |
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP suppresses the TGF-β pathway and the t...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP exerts significant effects against chemoresis...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that Mrs. Belén Toledo Cutillas MSc, Joint Resear...
A Scientific Poster Describing a Novel Therapeutic Strategy Decreasing the Influence of the Tumor Microenvironment Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments fo...
PRP May Help Overcome Growth of Fibrotic Tissue Surrounding Resistant Tumors Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring an...
PRP Exerts Effects Against Tumor Microenvironment Lowering Potential for Drug Resistance Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suf...
Presentation Times and Weblinks Released for Over 35 Presenting Companies Wednesday and Thursday, November 9-10, 2022 NEW YORK, NY / ACCESSWIRE / November 8, 2022 / Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day November Micro-Cap Co...
Propanc Biopharma (OTC: PPCB) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. The company’s novel pro...
Wednesday & Thursday, November 9 – 10, 2022 Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastat...
Company’s Lead Joint Researcher Professor Perán to Present Latest PRP Research Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients s...
News, Short Squeeze, Breakout and More Instantly...
Propanc Biopharma Inc Company Name:
PPCB Stock Symbol:
OTCMKTS Market:
Propanc Biopharma Inc Website:
British Journal of Cancer Concludes Tumor cell-intrinsic PD-L1 function promotes EMT Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recu...
Certificate of Grant Received for “Cancer Treatment” Patent from IP Corporation of Malaysia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patient...
Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that a certificate of grant for the Company’s &...